Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, ...
Avanos Medical, Inc. (NYSE: AVNS) is a medical technology and device company that develops and commercializes solutions intended to improve patient outcomes in two major areas: chronic care and non-opioid pain management/recovery. The company’s chronic care offerings focus on digestive health and patient nutrition support, including products such as Mic-Key ...Avanos Medical, Inc. (NYSE: AVNS) is a medical technology and device company that develops and commercializes solutions intended to improve patient outcomes in two major areas: chronic care and non-opioid pain management/recovery. The company’s chronic care offerings focus on digestive health and patient nutrition support, including products such as Mic-Key enteral feeding tubes, Corpak patient feeding systems, and NeoMed solutions for neonatal and pediatric patients. In respiratory health, Avanos provides closed airway suction systems and related airway management devices, marketed under brands including Ballard, Microcuff, and Endoclear.
In pain management, Avanos supplies non-opioid therapies designed for acute pain relief and post-procedural recovery, such as On-Q and ambIT surgical pain pumps. It also sells Game Ready cold and compression therapy systems. For interventional pain, the company offers minimally invasive treatment options such as Coolief for longer-term pain alleviation. These offerings reflect a device-centric approach: Avanos primarily provides hardware-based therapies and supportive medical device systems that are used by clinicians in clinical settings and, in some cases, as part of broader care pathways.
Business-wise, Avanos distributes its products through a blend of direct selling to hospitals and healthcare providers and via third-party wholesale distributors. This helps it reach end-user facilities across a broad geography—North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America—aligning with the company’s stated global footprint.
From an operational and commercial standpoint, the company competes in medical devices where clinical evidence, product reliability, and distributor/channel relationships matter. Its product catalog spans multiple clinical specialties (nutrition support, airway management, and pain therapy), which can diversify end-market demand but also requires robust regulatory, manufacturing, and quality systems across devices.
Financially (based on the provided dataset snapshot), Avanos shows notable metrics typical for a medical device manufacturer, including meaningful gross margin (reported around 0.486 in the dataset) but also negative profitability measures over the most recent trailing twelve months snapshot (negative operating and net margins). The dataset also indicates positive current liquidity (current ratio shown as ~2.48) and working capital remaining positive, suggesting the company maintains working-capital capacity even during periods of weaker earnings.
Key people referenced in the provided materials include CEO David C. Pacitti, along with other senior executives mentioned on the company’s site. Founded in 2014 and headquartered in Alpharetta, Georgia, Avanos traces its corporate origins to earlier activity under Halyard Health and later adopted the Avanos Medical, Inc. name in June 2018. With approximately 2,200 full-time employees worldwide (and other reported headcount ranges in the provided materials), Avanos operates at a scale suitable for multi-product medical device commercialization.
Overall, Avanos’ strategic focus is to deliver clinically superior device solutions for patient recovery and chronic care support, emphasizing non-opioid pain management options and enteral feeding technologies designed for everyday clinical use.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$701.2M
+1.9%
+0.7%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-67.9M
+82.7%
+37.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+49.8%
-10.2%
+2.1%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-8.8%
-251.1%
+113.6%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-9.7%
+83.0%
+36.9%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$43.1M
-48.0%
-177.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
+6.1%
-49.0%
-177.4%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
16.6%
-19.2%
+6.7%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.15x
-9.3%
+15.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Good morning, ladies and gentlemen, and welcome to Avanos Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Also note that this call is being recorded on February 24, 2026. I would now like to turn the conference over to Jason Pickett, Vice President, Corporate Finance and Treasurer.
Jason Pickett: Good morning, everyone, and thanks for joining us. It's my pleasure to welcome you to Avanos' 2025 Fourth Quarter and Full Year Earnings Conference Call. Presenting today will be Dave Pacitti, CEO; and Scott Galovan, Senior Vice President and CFO. Dave will review our fourth quarter and full year results and the current business environment. Scott will share additional details regarding these topics and provide our 2026 planning assumptions. We will finish the call with Q&A. A presentation for today's call is available on the Investors section of our website, avanos.com. As a reminder, our comments today contain forward-looking statements related to the company, our expected performance and current economic conditions, including risks relating to ongoing tariff negotiations and our industry. No assurance can be given as to future financial results. Actual results could differ materially from those in the forward-looking statements. For more information about forward-looking statements and the risk factors that could influence future results, please see today's press release and risk factors described in our filings with the SEC. Additionally, we will be referring to adjusted results and outlook. The press release has information on these adjustments and reconciliations to comparable GAAP financial measures. Now I'll turn the call over to Dave.
David Pacitti: Thanks, Jason, and good morning, everyone. I'm pleased to report that we delivered solid fourth quarter and full year results driven by the excellent progress we made advancing our strategic priorities. Fueled by the strong execution of our commercial teams, we delivered full year net sales of $701 million, exceeding the range that we revised following Q3. Additionally, we finished at the high end of our earnings guidance range, which was also revised upwards following Q3 and generated $0.94 of adjusted diluted earnings per share during the year. While the impact of tariffs in 2025 obscured the profitability of the company, our team took steps to mitigate their impact, and we will see the benefits of those measures starting this year. Moreover, we are closely evaluating the potential impact of the recent Supreme Court rulings on tariffs and monitoring subsequent actions by the administration. Once there is more clarity on how that ruling may impact our financial outlook, we will pass that information along to the investment community in subsequent updates. In the meantime, and as you will hear on the call today, please note that our tariff mitigation initiatives are firmly on track. 2025 represents an important period in the continued evolution of Avanos. Over the …
